University of Texas System

Merck Sharp + Dohme Corp.

Acumen Pharmaceuticals, Inc.

Washington University

Immune-onc Therapeutics, Inc.

Ningyan Zhang

Zhiqiang An

Chengcheng Zhang

Mi Deng

Xun Gui

Wei Xiong

Paul J Shughrue

Philipp Erich Scherer

Weirong Wang

Fubao Wang

Wei-Qin Zhao

Alexander McCampbell

Renee C Gaspar

Min Xu

Qiang Liu

Anil K Sood

Jean X Jiang

Manuel A Riquelme

Sumin Gu

X Charlene Liao

William F Goure

Junke Zheng

Shangang Zhao

Hui Deng

Naomi Ledene Sayre

Alexander Mccampbell

Dai Wang

Aimin Tang

Rong Li

Tong-Ming Fu

Abigail L Wolfe

Sha Ha

Mary J Savage

Franz F Hefti

Jingjing Xie

Xiujie Sun

Dawei Bu

Tao Huang

Jaehyup Kim

The present disclosure relates to antibodies binding to tumor discoidin domain receptor 1 (DDR1) and the uses of the antibodies in detecting and treating cancer.

DDR1 antibodies and uses thereof

Aspects of the present invention relate to methods and reagents for increasing chemosensitivity to platinum-based chemotherapy. In one aspect, a method of increasing chemosensitivity to platinum-based chemotherapy is provided, comprising administering to a patient in need thereof an effective amount of an endotrophin-neutralizing agent. The agent can be a monoclonal antibody, or fragment thereof, capable of binding to the C5 domain of the alphas chain of collagen VI. In some embodiments, the method can further include administering an effective amount of thiazolidinedione to said patient.

Monoclonal antibodies against endotrophin and the use thereof

The present disclosure provides an isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to leukocyte immunoglobulin-like receptor 4 (LILRB4). In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, modulates the activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, activates LILRB4. In certain embodiments, the antibody or antigen binding fragment, when bound to LILRB4, suppresses activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, specifically blocks binding of ApoE to LILRB4. In another aspect, there is provided a method of treating or ameliorating the effects of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the antibody or an antigen-binding fragment thereof or an engineered cell as provided herein.

LILRB4 antibodies and uses thereof

Isolated or recombinant anti-EGFL6 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.

EGFL6 specific monoclonal antibodies and methods of their use

Antibody antigen binding domains which specifically binds human leptin comprises Vor VCDR1, CDR2 and CDR3 sequences of an hLept antibody. The antibody antigen binding domains and antibodies thereof are useful to treat obesity and diabetes.

Leptin antibodies and method of reducing leptin

Antibodies that bind to connexin 43 hemichannels and inhibit, or activate, channel opening are provided. In certain aspects, methods for detecting or treating cancers with antibodies that activate Cx43 channel opening are also provided. Likewise, methods for treating inflammatory diseases (e.g., osteoarthritis) and neurological injuries (e.g., spinal cord injury) with antibodies that inhibit Cx43 channel opening are provided.

Methods of treating metastasis, including inhibiting bone cancer metastasis, by administering an antibody which binds connexin 43 (Cx43) hemichannel

Provided herein are methods and compositions for the identification of modulators of ApoE-induced LILRB activation. Also provided herein are methods of treating cancer comprising the administration of an inhibitor of ApoE-induced LILRB activation. Also provided are methods of treating autoimmune disease or inhibiting the onset of transplant rejection or treating an inflammatory disorder comprising administering an agonist of ApoE-induced LILRB activation to a subject.

Methods for identifying LILRB-blocking antibodies

Leptin antibodies

The present disclosure is directed to antibodies binding to LILRBs and methods of detecting and treating cancer therewith.

Anti-LILRB antibodies and their use in detecting and treating cancer

The present disclosure is directed to antibodies binding to LAIR 1 and their treating cancer, inflammation, immune-related diseases or transplantation.

Anti-leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) monoclonal antibodies and method of use thereof to treat cancer

The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (CMV). The antigen binding proteins of the invention are useful as a prophylactic and/or therapeutic agent for preventing and/or treating CMV infections in a patient in need thereof. Also encompassed by the invention are pharmaceutical compositions comprising the antigen binding proteins of the invention and a pharmaceutically acceptable carrier. The invention further relates to methods of using the antigen binding proteins and pharmaceutical compositions of the invention for the prevention or treatment of CMV infection in patients in need thereof.

CMV neutralizing antigen binding proteins

Isolated or recombinant anti-HER3 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.

HER3 specific monoclonal antibodies for diagnostic and therapeutic use

Methods of treating an osteolytic tumor and spinal cord injury by administering connexin (Cx) 43 hemichannel-binding antibodies

Growing community of inventors

Houston, TX, United States of America

Ningyan Zhang